Gamma-Hydroxybutyrate Formulation for Once-Nightly Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current modified release formulations of sodium oxybate for narcolepsy have low bioavailability and inconvenience patients with multiple doses and high sodium intake, leading to suboptimal therapeutic effects and compliance issues.
Innovation Solution
A modified release formulation of gamma-hydroxybutyrate that rapidly releases half of its dose in acidic medium and the other half in phosphate buffer, achieving bioavailability comparable to immediate release liquid solutions administered twice nightly, with a convenient once-nightly dosing and reduced sodium content.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If modified release formulations of sodium oxybate are used, then patient convenience is improved by reducing dosing frequency, but bioavailability deteriorates leading to suboptimal therapeutic effects
Solution Approach 1:
The formulation is divided into two distinct portions: an immediate release portion containing enteric-coated pellets that release drug rapidly in acidic medium, and a modified release portion containing uncoated or differently coated pellets that release drug more slowly. This segmentation allows the formulation to provide both immediate therapeutic effect and sustained release, achieving once-nightly dosing while maintaining bioavailability comparable to twice-nightly immediate release dosing.
Solution Approach 2:
Different portions of the formulation have different release properties tailored to specific needs. The enteric-coated pellets are designed to resist gastric acid and release in intestinal pH, while the uncoated or differently coated pellets release more rapidly. This local differentiation of release characteristics within the same formulation enables optimized pharmacokinetics for once-nightly administration.
2Reliability
If immediate release liquid solution is administered twice nightly, then bioavailability is maintained at adequate levels, but patient compliance deteriorates due to multiple doses and high sodium intake
Solution Approach 1:
The formulation merges immediate release and modified release mechanisms into a single oral dosage form. The enteric-coated pellets provide rapid release upon reaching intestinal pH, while the modified release portion extends drug availability. This combination in one formulation allows once-nightly dosing with bioavailability comparable to twice-nightly immediate release dosing, significantly improving patient compliance.
Solution Approach 2:
The formulation changes the release rate parameter by using different coating formulations on different portions of pellets. The enteric coating changes the release profile from immediate to delayed/modified, enabling the drug to be released over an extended period from a single dose, thereby maintaining therapeutic levels throughout the night without requiring multiple administrations.
3Reliability
If high dose sodium oxybate is administered to achieve therapeutic effect, then therapeutic effectiveness is improved, but harmful factors increase due to high sodium intake and side effects
Solution Approach 1:
The modified release portion of the formulation ensures continuous drug release over the treatment period, maintaining therapeutic drug levels throughout the night from a single dose. This continuous action improves therapeutic effectiveness while allowing lower total dosing compared to multiple immediate release doses, thereby reducing cumulative sodium intake and associated side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides improved bioavailability and therapeutic effectiveness with reduced residual drug content, enhancing patient compliance and safety by mimicking the pharmacokinetic profile of twice-nightly immediate release sodium oxybate while allowing a single daily dose.
Implementation Method 1
rapidly releases half of its dose in acidic medium and the other half in phosphate buffer
Data Source
AI summary
Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.